Shift Pharmaceuticals is developing Antisense Oligonucleotides as drug candidates for a variety of genetic disorders, including Charcot Marie Tooth Syndrome (CMT1A) and Spinal Muscular Atrophy (SMA). Rather than alleviating certain disease side effects, these molecules “SHIFT” the body’s natural protein production back into alignment effectively addressing the core cause of the disease. We are supported with funding from the NIH, DoD, CMT Research Foundation, and Gwendolyn Strong Foundation.
Looking for a particular Shift Pharmaceuticals employee's phone or email?
Shift Pharmaceuticals Questions
The Shift Pharmaceuticals annual revenue was $4 million in 2026.
Steve O'Connor is the CEO of Shift Pharmaceuticals.
1 people are employed at Shift Pharmaceuticals.
Shift Pharmaceuticals is based in Kansas, Oklahoma.
The NAICS codes for Shift Pharmaceuticals are [32541, 3254, 325, 32].
The SIC codes for Shift Pharmaceuticals are [283, 28].
Top Shift Pharmaceuticals Employees
-
Steve O'Connor
CEO at Shift Pharmaceuticals
Kansas City, MO, US35+
Related Companies
